94 related articles for article (PubMed ID: 11712084)
1. Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer.
Kasahara K; Taguchi T; Inoue K; Shuin T; Kariya S; Yoshida S; Furihata M
Int J Mol Med; 2001 Dec; 8(6):667-73. PubMed ID: 11712084
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapy.
Kasahara K; Taguchi T; Yamasaki I; Karashima T; Kamada M; Yuri K; Shuin T
Int J Oncol; 2001 Sep; 19(3):543-9. PubMed ID: 11494034
[TBL] [Abstract][Full Text] [Related]
3. Numerical chromosomal changes in metastatic prostate cancer following anti-androgen therapy: fluorescence in situ hybridization analysis of 5 Japanese cases.
Karashima T; Taguchi T; Yoshikawa C; Kamada M; Kasahara K; Yuri K; Shuin T
Cancer Genet Cytogenet; 2000 Jul; 120(2):148-54. PubMed ID: 10942807
[TBL] [Abstract][Full Text] [Related]
4. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
5. [High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].
Kasahara K; Inoue K; Karashima T; Inoue Y; Kariya S; Inomata T; Yoshida S; Shuin T
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):572-8. PubMed ID: 11517568
[TBL] [Abstract][Full Text] [Related]
6. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate.
Syed AM; Puthawala A; Sharma A; Gamie S; Londrc A; Cherlow JM; Damore SJ; Nazmy N; Sheikh KM; Ko SJ
Cancer Control; 2001; 8(6):511-21. PubMed ID: 11807421
[TBL] [Abstract][Full Text] [Related]
7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
8. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
9. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
10. [Combined treatment of localized prostate cancer with HDR-Iridium 192 remote brachytherapy and external beam irradiation].
Andreopoulos D; Piatkowiak M; Krenkel B; Schleicher UM; Wolff JM
Strahlenther Onkol; 1999 Aug; 175(8):387-91. PubMed ID: 10481770
[TBL] [Abstract][Full Text] [Related]
11. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
12. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
13. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma.
Borghede G; Hedelin H; Holmäng S; Johansson KA; Aldenborg F; Pettersson S; Sernbo G; Wallgren A; Mercke C
Radiother Oncol; 1997 Sep; 44(3):237-44. PubMed ID: 9380822
[TBL] [Abstract][Full Text] [Related]
15. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
Martinez AA; Gonzalez J; Ye H; Ghilezan M; Shetty S; Kernen K; Gustafson G; Krauss D; Vicini F; Kestin L
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):363-70. PubMed ID: 21195875
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
19. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial.
Nickers P; Coppens L; de Leval J; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jun; 79(3):329-34. PubMed ID: 16780976
[TBL] [Abstract][Full Text] [Related]
20. High-dose-rate brachytherapy with or without intensity modulated radiation therapy as salvage treatment for an isolated, gross local recurrence of prostate cancer post-prostatectomy.
Strom TJ; Wilder RB; Fernandez DC; Mellon EA; Saini AS; Hunt DC; Biagioli MC
Brachytherapy; 2014; 13(2):123-7. PubMed ID: 24269146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
